278 results about "Antigenic peptide" patented technology

The invention relates to the technical field of biological information, in particular to an immunoreaction evaluation method based on tumor neoantigen activity sorting. The method comprises the following steps: obtaining genome data of tumor and normal tissues through whole exon sequencing, extracting multi-dimensional features of candidate somatic mutation, and screening by combining a Gaussian mixture model and a Transform model to obtain a high-confidence mutation genome set; predicting the HLA genotype of a patient based on sequencing data, translating and mutating into a peptide fragment, predicting the binding affinity of the peptide fragment and an MHC molecule by using an XGBoost model, and calculating a new antigen activity score sequence in combination with various parameters; and finally, synthesizing a new antigen peptide fragment according to a sorting result, carrying out in-vitro co-culture to detect an IFN-gamma secretion result, and dynamically optimizing a characteristic combination coefficient through a PPO algorithm to realize intelligent iterative updating, so that the accuracy of new antigen screening and the immunoreaction prediction capability are remarkably improved.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Provided are an antigenic peptide having multiple KRAS variant peptides linked thereto, mRNA encoding same, DNA encoding same, an immunogenic composition comprising an antigenic peptide having multiple KRAS variant peptides linked thereto or an mRNA encoding same, and a method for inducing an immune response to the KRAS variant peptides in a subject.

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.

The invention provides a new antigen immunogenicity prediction method and system based on multi-feature fusion, and belongs to the technical field of machine learning, and the method comprises the steps: inputting a candidate peptide fragment sequence into an antigen intracellular processing prediction model to obtain a score representing the intracellular processing capability; inputting the candidate peptide fragment sequence into a pre-trained Transform model to obtain a sequence vector representation of the candidate peptide fragment; training an immunogenicity prediction model by taking the immunogenicity related characteristics, the sequence vector representation of the candidate peptide fragment and the score representing the intracellular processing capacity as a training sample; and screening the target candidate peptide fragment sequence by using the immunogenicity prediction model to obtain the tumor neoantigen. According to the method, the scoring model special for evaluating the intracellular processing and presentation capacity of the antigen peptide is constructed, the scoring model is output as a key feature, efficient fusion and learning are carried out on the key feature, multiple immunogenicity-related biological features and sequence vector representation of candidate peptide fragments, and the accuracy and reliability of tumor neoantigen immunogenicity prediction can be remarkably improved.

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention discloses an HLA and antigen peptide combination prediction method based on interactive attention, and belongs to the technical field of computational biology. The method comprises the following steps: 1, collecting HLA allele and unique peptide fragment data, and constructing an HLA and antigen peptide binding data set; 2, constructing an HLA and antigen peptide binding prediction model, and training the prediction model by using the HLA and antigen peptide binding data set to obtain a trained prediction model; and step 3, inputting the HLA sequence and the antigen peptide sequence into the prediction model to obtain a prediction result of combination of the HLA and the antigen peptide. According to the method, prediction tasks based on a sequence and a structure are integrated into a unified model, and the potential of the pHLA about the sequence and the structure is analyzed and predicted. Compared with an existing method, the two-dimensional evaluation provides a more comprehensive antigen immunogenicity view angle, and a new insight is provided for the quality of a new antigen for triggering an immunoreaction.

The present invention relates to an antigenic peptide targeting FLT3-D835 mutation and its application in tumor immunotherapy. Specifically, the present invention provides an antigenic peptide for eliciting an immune response targeting FLT3-D835 mutation. Compared with the lack of affinity between the wild-type polypeptide and HLA-A * 02:01 molecule, the antigenic peptide of the present invention has high affinity for HLA-A * 02:01 molecule. The present invention also provides the application of the antigenic peptide of the present invention. The antigenic peptide of the present invention has good immunogenicity, can activate specific immune responses, and has important clinical significance for targeting the clearance of leukemia cells, stabilizing the remission state of AML patients, and prolonging the disease-free survival time.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The invention relates to the technical field of biological medicine, and provides a ginseng cell engineering tumor vaccine as well as a preparation method and application thereof. The ginseng cell engineering tumor vaccine comprises an exosome derived from a recombinant ginseng cell capable of expressing a tumor antigen; the recombinant ginseng cell capable of expressing the tumor antigen is obtained by introducing a recombinant plasmid containing tumor antigen DNA into a ginseng cell. According to the invention, ginseng cells in Chinese herbal medicines are taken as host cells for recombinant expression of tumor antigens, large-scale production of tumor vaccines can be realized through construction of an engineering recombinant cell system, biocompatibility and uniformity of the vaccines can be maintained, and safety risks can be reduced. Meanwhile, the prepared tumor antigen recombinant expression ginseng cell exosome can integrate the antigen, an adjuvant and a carrier, and the antigen phagocytosis, maturation and antigen peptide presentation capabilities of APCs are enhanced.

The invention relates to the technical field of antibodies, in particular to antigen peptides of human PP1 alpha protein and Thr320 site phosphorylated protein of the human PP1 alpha protein, and a preparation method and application of an antibody of the antigen peptides of the human PP1 alpha protein and the Thr320 site phosphorylated protein. The invention provides an antigen peptide of human PP1 alpha protein and Thr320 site phosphorylated protein thereof, the antigen peptide has obvious advantages in the aspects of immunogenicity and the like, animals can be induced to generate high-level antibodies, and the generated antibodies have high specificity, affinity and titer. Based on the antigen peptide, the invention provides an anti-human PP1 alpha protein or a polyclonal antibody with phosphorylated Thr320 site thereof and a preparation method thereof, the polyclonal antibody has the characteristics of strong specificity, high affinity and high titer, and through immunoblotting and immunohistochemical verification, the polyclonal antibody can be used for preparing the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein. The probe shows good specificity and sensitivity in detection of phosphorylation modification of human PP1 alpha protein and Thr320 site thereof, and has a good application prospect.

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

The invention discloses application of an NR1D1 protein phosphorylation site in preparation of cerebral hemorrhage treatment drugs, and belongs to the technical field of molecular biology. According to the invention, the specific phosphorylation site and phosphorylation modification level of the NR1D1 protein are determined for the first time, and the NR1D1 protein can be used as a key marker for evaluating the secondary nerve injury degree of the hemorrhagic cerebral apoplexy and developing treatment and / or alleviation of the hemorrhagic cerebral apoplexy; a specific antigen peptide and an antibody for accurately detecting the NR1D1 protein phosphorylation site are further constructed, and an efficient tool is provided for molecular evaluation of hemorrhagic stroke secondary nerve injury; meanwhile, polypeptide molecules capable of inhibiting NR1D1 protein phosphorylation are researched and developed, through the dual effects of specifically blocking the phosphorylation process and reducing protein degradation, necrosis of brain tissues around hematoma after hemorrhagic cerebral apoplexy is relieved, secondary dyskinesia is improved, and the effect of inhibiting NR1D1 protein phosphorylation is achieved. And a brand new scheme is provided for molecular evaluation and targeted intervention of hemorrhagic stroke secondary nerve injury.

The present disclosure provides T cell receptors (TCRs) that bind to antigenic peptides of MAGE-A10 presented by HLA-A molecules. Also provided are nucleic acids encoding such TCRs, vectors comprising such nucleic acids, cells comprising such TCRs, nucleic acids and vectors, and compositions comprising such TCRs, nucleic acids, vectors, and cells. Also provided are methods for treating diseases / conditions using, and medical uses of, such TCRs, nucleic acids, vectors, cells and compositions.

The invention provides an MHC presentation peptide fragment prediction method and system based on multi-modal deep learning. The method comprises the following steps: constructing a multi-species MHC-peptide fragment combination data set; carrying out single genotype analysis on the multi-allele MHC-peptide fragment data in the multi-species MHC-peptide fragment combination data set, and determining a unique MHC-peptide fragment corresponding relationship; performing multi-sequence alignment and feature alignment on the cross-species MHC sequences, and extracting core site information representing MHC molecular polymorphism by adopting a frequency weighted amino acid feature distance algorithm; and constructing a multi-modal deep learning model, integrating MHC sequence features and peptide fragment sequence features, and predicting the binding capacity of MHC molecules and peptide fragments. According to the method, the high-order interaction characteristics between the MHC and the antigen peptide fragment can be more comprehensively and effectively captured.

Featured are devices, systems, and methods of use for detecting binding of polynucleotide-peptide conjugate-major histocompatibility complex (pMHC) monomers to a T cell receptors (TCR) on a T cell, and the use of a peptide library to detect binding of antigenic peptides in a pMHC monomer to a T cell receptor (TCR) on a T cell.

The invention provides a preparation method and application of a polyclonal antibody for recognizing IL-33 protein K6 site lactic acid modification, and belongs to the technical field of biological medicine, the invention discloses that lactic acid modification of IL-33 protein 6th lysine (Lys6) plays a key role in occurrence and development of liver cancer, and experiments prove that the site lactic acid promotes liver cancer cell proliferation and tumor growth; based on the discovery, the invention innovatively proposes that Lys6 lactic acid is used as a new target for tumor diagnosis and treatment, and successfully develops an antigen peptide and an antibody tool for specifically recognizing the modification site; the preclinical invention shows that the progress of the liver cancer can be effectively inhibited by blocking the Lys6 lactylation, the constructed detection system shows high sensitivity and specificity in liver cancer diagnosis, and the developed targeted antibody drug also has remarkable anti-tumor activity.

The application discloses a kind of recombinant polypeptide and its application in preparation of the drug for treating autoimmune disease.The polypeptide includes the following amino acid sequence: X1X2EX3RHRFRQLDX4;Wherein, X1 is S or A, X2 is E or Q, X3 is M or I, X4 is S or T;The length of the polypeptide is 13-18 amino acids.The polypeptide provided by the application has stronger immunogenicity, is the important antigen peptide of chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS, type III prostatitis) and can be induced immune tolerance using the polypeptide, to provide effective treatment scheme for treating autoimmune disease (for example, type III prostatitis).The application also provides a kind of method for constructing mouse EAP model, using only one kind of adjuvant CFA, i.e.can successfully construct the model most matched with human chronic prostatitis / chronic pelvic pain syndrome.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano vaccine based on GD2 mimetic peptide as well as a preparation method and application of the nano vaccine. The nano vaccine provided by the invention comprises a GD2 mimetic peptide, an STING agonist and a polymer carrier, wherein the STING agonist is used as an immunologic adjuvant. The antigen peptide (GD2 mimic peptide 47-LDA) and the adjuvant (STING agonist) are wrapped in the micelle to prepare the nano vaccine GD2-NV, so that the druggability of the antigen peptide and the STING agonist is improved, and the accumulation of drug tumors and drainage lymph node parts is improved. Besides, the nano vaccine can respond to a lysosome acid environment, realize lysosome escape, enhance antigen cross presentation of DC, activate an STING pathway, improve infiltration and activation degrees of CD8 + T cells, induce lasting humoral immune response and inhibit growth and recurrence of tumors, and is good in biological safety.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

A method is provided for treating a subject with cancer using a recombinant polypeptide comprising a DRα1 domain containing a glutamine residue at the position corresponding to amino acid 45 of SEQ ID NO: 1 or SEQ ID NO: 2, or an antigenic peptide covalently bound to a portion thereof. In some cases, the subject has a tumor that is resistant to immune checkpoint blockade treatment and / or does not express a BRAF mutation. The present invention provides, for example, a method for treating a subject with cancer, comprising administering to the subject a therapeutically effective amount of a recombinant polypeptide comprising a DRα1 domain containing a glutamine residue at the position corresponding to amino acid 50 of SEQ ID NO: 1 or SEQ ID NO: 2, or an antigenic peptide covalently bound to a portion thereof; or a nucleic acid encoding the recombinant polypeptide.

Methods of analyzing the presence or absence of immune cells capable of binding to an antigen peptide in a sample from one or more individuals are provided. Also provided are methods of detecting or treating cancer or a tumor, a pathogen infection, or an autoimmune disease. A display moiety is provided having particles associated with a plurality of MHC-peptide complexes, where at least two MHC-peptide complexes are different. Also provided are bait compositions having a plurality of display portions and methods of analyzing immune cells by using the display portions or bait compositions as screening tools.

The invention belongs to the technical field of tolerogen vaccines, and particularly relates to a tolerogen vaccine for treating multiple sclerosis and a preparation method and application of the tolerogen vaccine. The tolerogen vaccine comprises myelin basic protein, protein lipid protein and an antigen peptide fragment composition of myelin oligodendroglia glycoprotein, the preparation method comprises the following steps: S1, preparing a polypeptide mixture solution and an anionic liposome solution; s2, preparing a polypeptide mixture liposome preparation from the polypeptide mixture solution and the anionic liposome solution by adopting an injection method; s3, the polypeptide mixture lipidosome preparation is diluted, filtered and purified, and the lipidosome entrapped tolerogen vaccine is obtained.The multi-antigen tolerogen vaccine can be delivered through lipidosome, the limitation of a single antigen therapy is overcome, the immune tolerance induction effect is enhanced by means of the delivery advantage of lipidosome, and the application prospect is wide. And an efficient and safe novel precise therapy method is provided for MS treatment.

The invention provides a method for judging the reliability of mass spectrum identification of tumor neoantigen peptide fragments in cells and application thereof. The method comprises the following steps: constructing a model based on historical data of a tumor neoantigen mass spectrum identification experiment, scoring a positive group and a negative group based on the model, and calculating a boundary threshold value of the positive group and the negative group based on the scoring value; scoring a to-be-detected sample by using the trained model, and comparing the score with a boundary threshold value, so as to judge the reliability of the tumor neoantigen peptide fragment mass spectrum identification experiment of the to-be-detected cell sample.

The present disclosure relates to human antibodies specific to dermatomyositis antigen peptides, preparation methods and uses. Specifically, the present disclosure relates to a monoclonal antibody that specifically binds to MDA5 antigen protein, a preparation method of the monoclonal antibody and a use of the aforementioned monoclonal antibody in the preparation of a drug for the diagnosis, prevention or treatment of inflammatory myopathy or its complications. The antibody or antigen-binding fragment against MDA5 screened by the present disclosure specifically binds to MDA5 antigen, can be used as a reference standard for qualitative detection of MDA5 positivity, realizes qualitative or quantitative detection of the level of anti-MDA5 autoantibody in patients with inflammatory myopathy or its complications, and has important significance for the clinical diagnosis, disease monitoring and treatment of patients with DM, CAMD, DM-ILD, CADM-ILD and the like.

The application discloses an HLA-A*11:01 renal cell carcinoma tumor antigen short peptide derived from a long-chain non-coding RNA SLC12A5-AS1 and application thereof. The application provides a tumor antigen peptide, and an amino acid sequence of the tumor antigen peptide is shown as SEQ ID No. 1. It is found by the application that a complex formed by the short peptide and a corresponding HLA molecule (HLA-A*11:01) can be recognized by T cells, and an immune response is activated. The application provides a potential target for renal cell carcinoma treatment, and provides a new target screening direction for subsequent tumor antigen treatment of renal cell carcinoma.

The invention belongs to the field of medicine preparation, and particularly relates to bispecific cell membrane nanoparticles and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out in-vitro induction on primary CD4 + T cells by adopting TGF-beta and rapamycin to obtain regulatory T cells; enabling the distearoyl phosphatidyl ethanolamine-polyethylene glycol-active ester to react with the anti-CD4 antigen binding fragment, so as to obtain DP-aCD4; pre-incubating free aCD4 by the regulatory T cell, and co-incubating with DP-aCD4 to obtain an aCD4-regulatory T cell; the aCD4-regulatory T cells are mixed with an antigen peptide and an immunosuppressive agent, and the bispecific cell membrane nanoparticles AP-IA (at) aCD4Tn are prepared through a liposome extruder. After in-vivo administration of the bispecific cell membrane nanoparticles, generation of antigen-specific regulatory T cells can be efficiently induced, and accurate and efficient treatment and prevention of rheumatoid arthritis are realized.

We provide antigen-based immunotherapy, particularly cancer immunotherapy. [Solution] The present invention provides antigenic peptides that are different from human tumor antigen epitopes but have amino acid similarities thereto, and in particular share the same core sequence. The present invention further provides immunogenic compounds, nanoparticles, cells, and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.

The application belongs to the field of biological medicine, and provides an antibody combined with a specific antigen peptide of common pemphigus and application thereof, and the application uses the principle of phage display technology to perform in-vitro affinity screening on a constructed library, combines phages with target antigen Dsg3, elutes non-specific binders, retains phages combined with the antigen closely, and then amplifies the phages and performs multiple rounds of affinity enrichment; multiple rounds of panning are performed, and after 3-5 rounds of screening, phage clones with strong Dsg3 binding capacity and high specificity can be obtained.

This invention discloses an enhanced TCR and its uses. The enhanced TCR includes an α-chain variable region containing CDR1α, CDR2α, and CDR3α, and a β-chain variable region containing CDR1β, CDR2β, and CDR3β; wherein the enhanced TCR has a T30H mutation relative to the parental TCR's CDR1α, or the enhanced TCR has an S102H or G99H mutation relative to the parental TCR's CDR3α. The enhanced TCR provided by this invention is obtained by mutation based on the parental TCR, possessing a highly sensitive ability to bind target antigen peptides, significantly improving target cell recognition ability, and mediating the specific killing effect of effector cells on antigen-positive target cells, and exhibiting no allogeneic reaction to different HLA subtypes. It can be used to treat various cancers caused by KRAS G12D positivity.